Sensory nerves affected by genetic disease rescued with gene therapy
In the long human struggle against diseases that steal childhood one nerve at a time, a small trial at the National Institutes of Health has opened a door that many believed sealed shut. Fourteen children with giant axonal neuropathy — a fatal condition that quietly dismantles the nervous system from birth onward — received an experimental gene therapy delivered directly into their spinal fluid, the first such attempt in human history for this disease. The results, published in the New England Journal of Medicine, suggest not only that the therapy can slow the disease's march, but that nerves once thought lost may, under the right conditions, find their way back.
- GAN sentences children to wheelchairs by age eight and death by thirty, and until now no treatment of any kind existed to interrupt that trajectory.
- A single injection of a gene-carrying virus, threaded into the cerebrospinal fluid, reached the motor and sensory neurons that the disease destroys — a delivery route never before attempted in humans for this condition.
- At the highest doses tested, statistical modeling placed the probability of slowing motor decline at 99 percent, a figure that stunned researchers accustomed to incremental progress in rare disease trials.
- Six of the fourteen children regained measurable sensory nerve function — the first documented instance of sensory nerve rescue through gene therapy in any genetic degenerative disease.
- Two older participants died from their underlying disease during the trial, a reminder of how little time this population has, and how urgently the next phase — targeting younger patients earlier in the disease course — must begin.
Fourteen children with a rare and relentless nerve disease became the center of a medical milestone when researchers at the National Institutes of Health administered an experimental gene therapy directly into the fluid surrounding their spinal cords. The disease, giant axonal neuropathy, is caused by mutations that prevent nerve cells from clearing their own internal scaffolding. That scaffolding accumulates until the axons — the long fibers that carry signals between nerves — swell and collapse. Children with GAN typically lose the ability to walk by age eight or nine, and most do not survive past thirty.
The therapy, delivered as a single injection using a modified virus to carry functional copies of the defective gene, was tested at four escalating dose levels across the fourteen participants. Results published in the New England Journal of Medicine showed that at the highest doses, there was a 99 percent probability of slowing motor decline. More unexpectedly, six patients showed recovery of sensory nerve function — nerves that had either degraded or gone silent began producing measurable electrical signals again. Researchers described this as the first time sensory nerves had been rescued by gene therapy in any genetic degenerative disease.
Safety was closely monitored throughout the early-stage trial. One serious adverse event, a fever, was potentially linked to the therapy, and lesser side effects including headache, back pain, and spinal fluid inflammation were managed with corticosteroids. Two older participants died during the study from complications of their underlying disease, not from the treatment itself. The spinal fluid delivery route proved strategically valuable: it required lower doses and reduced immune interference, potentially opening the door to patients previously excluded from gene therapy trials due to prior viral exposure.
For the researchers, the sensory nerve recovery was the most historically significant finding — a suggestion that nerve damage in genetic disease may not always be permanent. The method is already being adopted by other gene therapy programs, and the next phase of trials will focus on younger children treated earlier in the disease course, when more nerve tissue remains to be saved.
Fourteen children with a rare, relentless nerve disease sat at the center of a medical milestone. Between 2015 and the years that followed, they received a single injection of experimental gene therapy delivered directly into the fluid surrounding their spines—the first time this approach had ever been tried in humans for giant axonal neuropathy, or GAN, a childhood neurodegenerative condition with no existing treatment and a typical lifespan measured in decades, not lifetimes.
GAN is a disease of accumulation. Mutations in the GAN gene prevent the body from breaking down intermediate filaments, the structural scaffolding inside nerve cells. Over time, these filaments pile up, bloating the axons—the long extensions that allow nerve cells to communicate—until they collapse entirely. A child with GAN might first stumble and move clumsily at age two or three. By eight or nine, most require a wheelchair. As the disease advances, the arms weaken, the legs fail, and eventually breathing and swallowing become impossible without mechanical support. Death typically arrives by age thirty.
The therapy, called scAAV9/JeT-GAN, works by using a modified virus to slip functional copies of the defective gene into nerve cells. The innovation was not just the therapy itself but where it went: directly into the cerebrospinal fluid bathing the spinal cord, allowing it to reach the motor and sensory neurons that GAN destroys. Researchers at the National Institutes of Health tested four different dose levels, starting with the lowest in the first two patients and gradually increasing. The results, published in the New England Journal of Medicine, showed something unexpected and striking. At the highest doses, the probability of slowing motor decline reached 99 percent. More remarkably, six of the fourteen patients experienced something that had never been documented before in a genetic degenerative disease: their sensory nerves, which are typically the first to fail in GAN, began to recover. Electrical measurements of nerve function increased, stabilized, or reappeared after being absent.
Safety remained the paramount concern in an early-stage trial. One serious adverse event—a fever—was potentially linked to the therapy. The treatment caused 129 lesser adverse events, including headache, back pain, irregular heartbeats, and inflammation in the spinal fluid that responded to corticosteroids. Two older patients who received the lowest dose died during the study period from complications of their underlying disease, not from the therapy itself. The overall picture was one of tolerability, a crucial finding when treating children with a fatal condition.
The choice to deliver the therapy through the spinal fluid rather than the bloodstream proved strategically important. It required lower doses and reduced the risk of triggering an immune response—a particular advantage for children who had already been exposed to adeno-associated virus, the modified virus used as the delivery vehicle. Previously, such children would have been excluded from gene therapy trials because their immune systems would attack the therapy. This method opens doors for patients who would otherwise have no options.
Dr. Carsten Bonnemann, the senior investigator and chief of the Neuromuscular and Neurogenetic Disorders of Childhood Section at the National Institute of Neurological Disorders and Stroke, described the sensory nerve recovery as historic. The finding suggested that nerve damage in genetic diseases might not be irreversible—that with the right intervention, cells could be coaxed back to function.
The trial represents a proof of concept that may extend far beyond GAN. Other researchers developing gene therapies have already begun adopting the spinal fluid delivery method, recognizing its advantages in dose efficiency and immune tolerance. The next phase will test whether the therapy works better when given to younger children or those earlier in the disease course, when more nerve tissue remains intact. For families living with GAN, the question is no longer whether gene therapy can help, but how to optimize it.
Notable Quotes
This marks the first time sensory nerves affected in a genetic degenerative disease have been rescued with gene therapy— Dr. Carsten Bonnemann, NINDS
The Hearth Conversation Another angle on the story
Why does it matter that this therapy was delivered into the spinal fluid rather than through the bloodstream?
It's about access and efficiency. The spinal fluid bathes the nerves that GAN attacks directly. You need less drug to reach the target, which means lower doses and fewer systemic side effects. It also sidesteps a major barrier: kids who've been naturally exposed to the virus used as a delivery vehicle would normally be rejected from trials because their immune systems would destroy the therapy. This method gets around that.
The fact that sensory nerves "woke up" again—what does that actually mean for a child living with this disease?
It means the damage might not be permanent. In GAN, sensory nerves are typically the first to fail. Patients lose feeling in their extremities. If those nerves can be rescued, it's not just a biological curiosity—it suggests that with the right genetic fix, you can restore function that was thought to be gone forever. That changes how we think about degenerative diseases.
Two patients died during the trial. How do you square that with calling it a success?
Both were older and received the lowest dose. They died from their underlying disease, not from the therapy itself. In a disease that's usually fatal by thirty, that's the baseline you're measuring against. The question isn't whether everyone survives—it's whether the therapy is safe enough to try and whether it slows the inevitable. Here, it did both.
What happens next?
They're planning to treat younger children, kids earlier in the disease course when more nerve tissue is still intact. The hope is that intervening sooner, before too much damage accumulates, will show even better results. This is still early-stage work, but the door is open now.